Cisen Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	3,553	3,972	4,451	4,049	3,773	3,666
Other Revenue	10.02	10.02	11.14	16.83	9.62	8.28
Revenue	3,563	3,982	4,462	4,066	3,783	3,674
Revenue Growth (YoY)	-16.26%	-10.77%	9.74%	7.50%	2.95%	-10.66%
Cost of Revenue	1,689	1,813	1,913	1,827	1,728	1,610
Gross Profit	1,875	2,168	2,550	2,239	2,055	2,064
Selling, General & Admin	1,153	1,367	1,600	1,544	1,455	1,355
Research & Development	291.41	342.64	374.88	335.17	334.35	309.58
Other Operating Expenses	26.85	-4.28	20.97	55.37	50.31	45.07
Operating Expenses	1,477	1,702	1,999	1,948	1,841	1,706
Operating Income	397.49	466.89	550.79	291.2	214.24	357.94
Interest Expense	-1.75	-6.95	-6.59	-4.29	-6.1	-9.8
Interest & Investment Income	169.19	101.87	85.7	53	90.18	83.09
Currency Exchange Gain (Loss)	0.54	0.54	0.55	-0.32	-0.62	-1.6
Other Non Operating Income (Expenses)	-7.75	-0.7	-1.27	-0.17	5.21	-3.55
EBT Excluding Unusual Items	557.72	561.66	629.19	339.41	302.91	426.09
Gain (Loss) on Sale of Investments	9.55	10.53	-10.37	-3.12	-6.09	23.03
Gain (Loss) on Sale of Assets	0.25	-0.14	0.59	0.97	0.27	0.17
Asset Writedown	-20.82	-0.63	-27.79	0.01	-0.04	-1.05
Other Unusual Items	13.45	4.36	4.24	28.92	39.09	36.28
Pretax Income	560.14	575.77	595.86	366.19	336.13	484.52
Income Tax Expense	63.31	60.83	70.43	13.92	2.23	47.16
Earnings From Continuing Operations	496.83	514.94	525.43	352.27	333.9	437.36
Minority Interest in Earnings	-4.03	-6.03	-4.09	-2.31	0.24	1.42
Net Income	492.8	508.91	521.34	349.96	334.15	438.78
Net Income to Common	492.8	508.91	521.34	349.96	334.15	438.78
Net Income Growth	-6.84%	-2.38%	48.97%	4.73%	-23.85%	-14.73%
Shares Outstanding (Basic)	456	454	453	454	452	452
Shares Outstanding (Diluted)	456	454	453	454	452	452
Shares Change (YoY)	0.89%	0.23%	-0.25%	0.65%	-0.18%	0.21%
EPS (Basic)	1.08	1.12	1.15	0.77	0.74	0.97
EPS (Diluted)	1.08	1.12	1.15	0.77	0.74	0.97
EPS Growth	-7.67%	-2.61%	49.35%	4.05%	-23.71%	-14.91%
Free Cash Flow	701.19	469.04	433.53	223.15	182.58	228.74
Free Cash Flow Per Share	1.54	1.03	0.96	0.49	0.40	0.51
Dividend Per Share	0.408	0.440	0.436	0.335	0.300	0.256
Dividend Growth	-37.80%	0.92%	30.15%	11.67%	17.19%	-4.48%
Gross Margin	52.61%	54.46%	57.14%	55.06%	54.32%	56.17%
Operating Margin	11.16%	11.73%	12.34%	7.16%	5.66%	9.74%
Profit Margin	13.83%	12.78%	11.68%	8.61%	8.83%	11.94%
Free Cash Flow Margin	19.68%	11.78%	9.71%	5.49%	4.83%	6.23%
EBITDA	603.19	683.33	781.54	519.77	432.08	517.92
EBITDA Margin	16.93%	17.16%	17.51%	12.78%	11.42%	14.10%
D&A For EBITDA	205.7	216.43	230.75	228.57	217.84	159.98
EBIT	397.49	466.89	550.79	291.2	214.24	357.94
EBIT Margin	11.16%	11.73%	12.34%	7.16%	5.66%	9.74%
Effective Tax Rate	11.30%	10.56%	11.82%	3.80%	0.66%	9.73%
Revenue as Reported	3,563	3,982	4,462	4,066	3,783	3,674
Advertising Expenses	-	1.47	0.82	0.2	0.51	2.83

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.